Back to results
US 2026/0308616 A1Published application
Purification of viruses and viral like particles
AssigneeInterius Biotherapeutics, Inc.
InventorsPHILIP R. JOHNSON, Bruce C. Schnepp, Ronnie M. Russell
Life of this patent
Estimating the term…
Abstract
Provided for herein are pseudotyped viral constructs comprising affinity binding polypeptides fused with glycoproteins, targeting moieties, or a combination thereof. Also provided for herein are methods of purifying and using the viral constructs provided for herein.
Claims51
A pseudotyped viral-like particle or viral vector comprising:
- an envelope comprising a recombinant virus glycoprotein, a targeting moiety for binding to a target cell, and at least a first affinity binding polypeptide, wherein the first affinity binding polypeptide is fused to the glycoprotein, the targeting moiety, or any combination thereof;
- and
- a nucleic acid molecule encoding a heterologous molecule of interest.
The pseudotyped viral-like particle or viral vector of claim 190, wherein the targeting moiety comprises an amino acid sequence having at least 85% identity to SEQ ID NO:
- 119 or SEQ ID NO:
- 120.
A pseudotyped viral-like particle or viral vector comprising:
- an engineered envelope comprising a recombinant virus glycoprotein, an engineered targeting moiety for binding to a target cell, and at least a first affinity binding polypeptide, wherein the at least a first affinity binding polypeptide is fused to the glycoprotein, and the glycoprotein comprises an amino acid sequence as set forth in SEQ ID NO:
- 25, SEQ ID NO:
- 29, SEQ ID NO:
- 30, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 39, SEQ ID NO:
- 40, SEQ ID NO:
- 41, SEQ ID NO:
- 42, SEQ ID NO:
- 43, SEQ ID NO:
- 44, SEQ ID NO:
- 45, SEQ ID NO:
- 46, SEQ ID NO:
- 47, SEQ ID NO:
- 49, SEQ ID NO:
- 50, SEQ ID NO:
- 52, SEQ ID NO:
- 53, SEQ ID NO:
- 55, SEQ ID NO:
- 56, SEQ ID NO:
- 58, SEQ ID NO:
- 59, SEQ ID NO:
- 61, SEQ ID NO:
- 62, SEQ ID NO:
- 64, SEQ ID NO:
- 65, SEQ ID NO:
- 66, SEQ ID NO:
- 67, SEQ ID NO:
- 74;
- SEQ ID NO:
- 77, SEQ ID NO:
- 79, or SEQ ID NO:
- 80;
- and
- a nucleic acid encoding a heterologous molecule of interest.
35 more elements
A pseudotyped viral-like particle or viral vector comprising:
- an engineered envelope comprising a recombinant virus glycoprotein, an engineered targeting moiety for binding to a target cell, and at least a first affinity binding polypeptide, wherein the at least a first affinity binding polypeptide is fused to the glycoprotein, and the at least a first affinity binding polypeptide fused to the glycoprotein comprises an amino acid sequence as set forth in SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 35;
- SEQ ID NO:
- 68, SEQ ID NO:
- 69, SEQ ID NO:
- 70, SEQ ID NO:
- 71, SEQ ID NO:
- 72, SEQ ID NO:
- 73, SEQ ID NO:
- 75, SEQ ID NO:
- 76, SEQ ID NO:
- 78, SEQ ID NO:
- 81, SEQ ID NO:
- 132, SEQ ID NO:
- 133, SEQ ID NO:
- 135, SEQ ID NO:
- 136, SEQ ID NO:
- 137, SEQ ID NO:
- 138, SEQ ID NO:
- 139, SEQ ID NO:
- 140, SEQ ID NO:
- 141, SEQ ID NO:
- 142, SEQ ID NO:
- 143, SEQ ID NO:
- 144, SEQ ID NO:
- 145, SEQ ID NO:
- 147, SEQ ID NO:
- 148, SEQ ID NO:
- 149, SEQ ID NO:
- 150, SEQ ID NO:
- 151, SEQ ID NO:
- 152, SEQ ID NO:
- 153, SEQ ID NO:
- 154, SEQ ID NO:
- 155, SEQ ID NO:
- 156, SEQ ID NO:
- 157, SEQ ID NO:
- 158, SEQ ID NO:
- 159, SEQ ID NO:
- 160, SEQ ID NO:
- 161, SEQ ID NO:
- 162, SEQ ID NO:
- 163, SEQ ID NO:
- 164, SEQ ID NO:
- 166, SEQ ID NO:
- 167, SEQ ID NO:
- 168, SEQ ID NO:
- 170, SEQ ID NO:
- 172, SEQ ID NO:
- 188, SEQ ID NO:
- 189, SEQ ID NO:
- 190, or SEQ ID NO:
- 191;
- and
- a nucleic acid encoding a heterologous molecule of interest.
57 more elements
A pseudotyped viral-like particle or viral vector comprising:
- an engineered envelope comprising a recombinant virus glycoprotein, an engineered targeting moiety for binding to a target cell, and at least a first affinity binding polypeptide, wherein the targeting moiety is an scFv comprising an amino acid sequence of SEQ ID NO:
- 101, SEQ ID NO:
- 102, SEQ ID NO:
- 119 or SEQ ID NO:
- 120, and the at least a first affinity binding polypeptide is fused to the targeting moiety;
- and
- a nucleic acid encoding a heterologous molecule of interest.
4 more elements
A pseudotyped viral-like particle or viral vector comprising:
- an engineered envelope comprising a recombinant virus glycoprotein, an engineered targeting moiety for binding to a target cell, and at least a first affinity binding polypeptide, wherein the targeting moiety is an scFv, and wherein the at least a first affinity binding polypeptide is fused to the targeting moiety and comprises an amino acid sequence of SEQ ID NO:
- 121, SEQ ID NO:
- 126, SEQ ID NO:
- 129, SEQ ID NO:
- 130, SEQ ID NO:
- 131, SEQ ID NO:
- 174, SEQ ID NO:
- 175, SEQ ID NO:
- 176, SEQ ID NO:
- 178, SEQ ID NO:
- 179, SEQ ID NO:
- 180, SEQ ID NO:
- 181, SEQ ID NO:
- 182, SEQ ID NO:
- 183, SEQ ID NO:
- 184, SEQ ID NO:
- 185, SEQ ID NO:
- 186, or SEQ ID NO:
- 187;
- and
- a nucleic acid encoding a heterologous molecule of interest.
18 more elements
A pseudotyped viral-like particle or viral vector comprising:
- an engineered envelope comprising a recombinant virus glycoprotein, an engineered targeting moiety for binding to a target cell, and at least two affinity binding polypeptides,
- wherein the recombinant virus glycoprotein is fused to a first affinity binding polypeptide and comprises an amino acid sequence of SEQ ID NO:
- 26, SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 35;
- SEQ ID NO:
- 68, SEQ ID NO:
- 69, SEQ ID NO:
- 70, SEQ ID NO:
- 71, SEQ ID NO:
- 72, SEQ ID NO:
- 73, SEQ ID NO:
- 75, SEQ ID NO:
- 76, SEQ ID NO:
- 78, SEQ ID NO:
- 81, SEQ ID NO:
- 132, SEQ ID NO:
- 133, SEQ ID NO:
- 135, SEQ ID NO:
- 136, SEQ ID NO:
- 137, SEQ ID NO:
- 138, SEQ ID NO:
- 139, SEQ ID NO:
- 140, SEQ ID NO:
- 141, SEQ ID NO:
- 142, SEQ ID NO:
- 143, SEQ ID NO:
- 144, SEQ ID NO:
- 145, SEQ ID NO:
- 147, SEQ ID NO:
- 148, SEQ ID NO:
- 149, SEQ ID NO:
- 150, SEQ ID NO:
- 151, SEQ ID NO:
- 152, SEQ ID NO:
- 153, SEQ ID NO:
- 154, SEQ ID NO:
- 155, SEQ ID NO:
- 156, SEQ ID NO:
- 157, SEQ ID NO:
- 158, SEQ ID NO:
- 159, SEQ ID NO:
- 160, SEQ ID NO:
- 161, SEQ ID NO:
- 162, SEQ ID NO:
- 163, SEQ ID NO:
- 164, SEQ ID NO:
- 166, SEQ ID NO:
- 167, SEQ ID NO:
- 168, SEQ ID NO:
- 170, SEQ ID NO:
- 172, SEQ ID NO:
- 188, SEQ ID NO:
- 189, SEQ ID NO:
- 190, or SEQ ID NO:
- 191,
- wherein the targeting moiety is an scFv,
- wherein the targeting moiety is fused to a second affinity binding polypeptide and comprises an amino acid sequence of SEQ ID NO:
- 121, SEQ ID NO:
- 126, SEQ ID NO:
- 129, SEQ ID NO:
- 130, SEQ ID NO:
- 131, SEQ ID NO:
- 174, SEQ ID NO:
- 175, SEQ ID NO:
- 176, SEQ ID NO:
- 178, SEQ ID NO:
- 179, SEQ ID NO:
- 180, SEQ ID NO:
- 181, SEQ ID NO:
- 182, SEQ ID NO:
- 183, SEQ ID NO:
- 184, SEQ ID NO:
- 185, SEQ ID NO:
- 186, or SEQ ID NO:
- 187;
- and
- a nucleic acid encoding a heterologous molecule of interest.
78 more elements
A method of purifying a pseudotyped viral-like particle or viral vector, the method comprising transfecting or transducing a packaging cell line with a nucleic acid molecule encoding for a recombinant virus glycoprotein, an engineered targeting moiety for binding to a target cell, and at least a first affinity binding polypeptide, wherein the first affinity binding polypeptide is fused to the glycoprotein, the targeting moiety, or any combination thereof;
- culturing the packaging cell line under conditions sufficient to produce the pseudotyped viral-like particle or viral vector;
- isolating the pseudotyped viral-like particle or viral vector;
- and purifying the pseudotyped viral-like particle or viral vector via use of the first affinity binding polypeptide included in the glycoprotein, the targeting moiety, or both.
Dependencies are inferred from the claim text.